Limited Capacity! Register Early to Secure Your Place

February 11-12, 2020 | San Diego, CA
www.lbx-summit.com

Liquid Biopsy For Precision Oncology Summit

Discover & Characterize Predictive Biomarkers, Improve Personalized Drug Development & Diagnose Cancer with More Precision, Sensitivity & Selectivity

Expert Speakers Include:

Howard Scher
Co-Chair, Head, D. Wayne Calloway Chair & Attending Physician
Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College

Emmanuelle di Tomaso
VP, Head Oncology Biomarkers
Bayer

Hua Fang
Clinical Biomarker Lead, Immuno-Oncology, Oncology Early Clinical Development
AbbVie

Sarah Paul
Principal Scientific Researcher & Biomarker Lead
Genentech

Jean-Francois Martini
Senior Director, Translational Oncology & Lead, Global Product Development
Pfizer

Lauren Leiman
Executive Director
BloodPAC

Proud to Partner With

GUARDANT epic sciences

Welcome to the 4th Liquid Biopsy for Precision Oncology Summit

With liquid biopsy now a focal point for drug developers, technologies are getting even better at detecting and diagnosing cancer, monitoring treatment response and aiding in patient selection. Now, the need to prove its **clinical utility** is key to advancing into routine healthcare practice.

Join biopharma, clinical and diagnostic teams at the ***4th Liquid Biopsy for Precision Oncology Summit*** to accelerate the translation of liquid biopsies into your clinical application, drive clinical adoption and reduce the barriers to providing improved patient outcomes and achieving successful commercial results.

This meeting allows you to **discover the latest technologies** and applications, demonstrating how to harness the improved specificity and sensitivity to characterize liquid biopsy samples and predictive biomarkers, such as **exosomes, CTCs, ctDNA** and **RNA** to expedite your drug development timelines.

From validating predictive biomarkers to effectively meeting unmet clinical need, join your drug development peers from **translational research, biomarker, early trial design** and **clinical oncology** departments who are striving to translate the clinical application of liquid biopsies into a patient reality.

What did past attendees say?

"Stellar, inclusive, insightful"
Caza Health

"A very good conference. The speed networking activity was a great start"
Sysmex

Key Topics for 2020:

Dana Farber Cancer Institute & **Ghent University** on harnessing sensitive technologies & developing assays with high accuracy to improve marker identification & analysis

Insights from **Ionis Pharmaceuticals** & **Biogazelle** on the impact of pre-analytical variables on trial outcomes & finding the best analyte for your application



Showcasing the latest advancements in clinical studies with **Pfizer**, **Genetech**, **MD Anderson Cancer Center** & **Halozyme** which are informing patient monitoring & resistance

Identifying the challenges & opportunities of utilizing liquid biopsy in the clinic with insight from **MSKCC** to better navigate remaining hesitations in healthcare

"Well organized, with speakers covering a variety of expertise"

YOUR EXPERT SPEAKERS

Kimberly Banks
Senior Director, Medical Affairs, BioPharma
Guardant Health

Christina Bender
Exploratory Biomarker & Oncology Commercialization Lead
Bristol-Myers Squibb

Benoit Destenaves
Director & Precision Medicine Lead
AstraZeneca

Emmanuelle di Tomaso
VP, Head Oncology Biomarkers
Bayer

Hua Fang
Clinical Biomarker Lead, Immuno-Oncology, Oncology Early Clinical Development
AbbVie

An Hendrix
Professor
Ghent University

Lauren Leiman
Executive Director
BloodPAC

Jean-Francois Martini
Senior Director, Translational Oncology & Lead, Global Product Development
Pfizer

G. Mike Makrigiorgos
Professor
Dana Farber Cancer Institute & **Harvard Medical School**

Robert McCormack
Independent

Palani Palaniappan
Chief Technology Officer
Epic Sciences

Sarah Paul
Senior Scientific Manager & Biomarker Lead
Genentech

Mark Routbort
MD, Professor, Hematopathology
University of Texas MD Anderson Cancer Center



Howard Scher
Co-Chair, Head, D. Wayne Calloway Chair & Attending Physician
Memorial Sloan Kettering Cancer Center & **Weill Cornell Medical College**

Leighla Tayefeh
Research Associate, Biomarker Development
Ionis Pharmaceuticals

Jo Vandesompele
Professor & Chief Scientific Officer
Ghent University & **Biogazelle**

CONFERENCE DAY ONE
TUESDAY, FEBRUARY 11, 2020

Christina Bender
Exploratory Biomarker & Oncology Commercialization Lead
Bristol-Myers Squibb

8.50 Chair's Opening Remarks

Harnessing Improved Technologies to Advance the Industry Applications of Liquid Biopsy

Benoit Destenaves
Director & Precision Medicine Lead
AstraZeneca

9.00 What's New? An Overview of the Liquid Biopsy Space

- Uncovering the latest advancements, challenges and strategies seen across the liquid biopsy field
- Discussing the current state of play on clinical use and uptake of liquid biopsies: How do we advance this even further?
- Where next? Taking a look into what's on the horizon for non-invasive tests and key next steps for drug developers

Kimberly Banks
Senior Director, Medical Affairs, BioPharma
Guardant Health

9.30 Accurate Biomarker Identification Through Digital Sequencing: Accelerating Adoption of ctDNA in Trials & the Clinic

- Lessons from 100,000 patients to improve assay performance
- Clinical trial case studies for faster enrollment and study insights
- Improving patient treatment and outcomes

10.00 Panel Discussion: Women in Precision Medicine

Coming soon. Uniting scientific and business leaders from all key stakeholders of the community, this keynote panel discussion will highlight the importance of a diverse workforce and provide actionable takeaways for increased advocacy in individual workplaces. Stay tuned!

10.45 Speed Networking

11.10 Morning Refreshments

Palani Palaniappan
Chief Technology Officer
Epic Sciences

11.30 Bridging the GAP in Liquid Biopsies – CTCs & cfDNA: A Comprehensive Approach to Detection & Monitoring of Cancer

- Cancer is a high complexity disease which requires a combination of biological insights from both genotypic and phenotypic analysis to guide precision medicine
- Circulating tumor cells (CTCs) and cell free DNA (cfDNA) liquid biopsies enable complementary information for clinical decisions, allowing for diagnosis, accurate prognosis, therapeutic target selection, as well as monitoring response and resistance to treatment
- Find out how these technologies enable a true Comprehensive Cancer Profiling from a single tube of blood to get all the biological insights needed

G. Mike Makrigiorgos
Professor
Dana Farber Cancer Institute & Harvard Medical School

12.00 Novel Digital PCR & Mutation Enrichment Technologies for the Analysis of Clinically Relevant DNA Alterations in Liquid Biopsies

- With the increasing interest in treatment assessment using liquid biopsy and circulating DNA, sensitive and multiplexed detection of tumor-derived alterations in blood are desirable
- We provide novel forms of digital PCR, as well as mutation enrichment-based real time PCR methods that (a) enable several orders of magnitude improvement of detecting mutations or microsatellite instability than currently possible; (b) are highly multiplex-able; (c) reduce cost of analysis
- Application in circulating DNA from clinical cancer samples will be presented

An Hendrix
Professor
Ghent University

12.30 Extracellular Vesicles in Disease Monitoring: Evaluating a New Analyte Approach for Liquid Biopsy

- Understanding the advantage of extracellular vesicles as a diagnostic and prognostic tool for certain applications
- Strategies to maximize marker detection from extracellular vesicles through purification and analysis techniques
- How are extracellular vesicles being applied? Evaluating the safety, predictive and diagnostic markers

13.00 Networking Lunch

Addressing Pre-Analytical Steps to Maximize Reliability of Trials & Ensure Quality Sample Management

Emmanuelle di Tomaso
VP, Head Oncology Biomarkers
Bayer

14.00 Leveraging Liquid Biopsies in Clinical Development Across a Portfolio

- Finding the specific driver of disease to inform target identification
- Overcoming key challenges in translation to clinical trials
- Exploring sensitivity levels required for biomarker and analyte types across a portfolio

Jo Vandesompele
Professor & Chief Scientific Officer
Ghent University & **Biogazelle**

14.30 Exploiting RNA in Liquid Biopsies for Precision Medicine Purposes

- Biofluids are rich sources of messenger RNA, circular RNA and microRNAs
- The Human Biofluid RNA Atlas: a novel compendium of human extracellular transcriptomes
- The Extracellular RNA Quality Control study: benchmarking plasma RNA transcriptome profiling

15.00 Afternoon Refreshments

Leighla Tayefeh
Research Associate, Biomarker Development
Ionis Pharmaceuticals

15.30 The Impact of Matrix Selection as a Pre-Analytical Variable on Blood-Based Protein Biomarker Quantification

- In the context of protein biomarkers measurements, the goal is to measure the levels that are circulating
- Understanding the impact of proper sample matrix selection is an important piece of this. Platelets and other circulating cells can release proteins during the process of coagulation
- Anticoagulants can affect the ability to detect different proteins. If the proper matrix is not selected the measurements may be incorrect

Lauren Leiman
Executive Director
BloodPAC

16.00 BloodPAC Data Common: Accelerating Data Sharing & Analysis

- Exploring the BloodPAC Data Common and its applications in liquid biopsy-based studies
- Heading for approval: Demostrating how having an FDA approved Data Common positively impacts your future studies
- Looking ahead to future directions and applications of the project

16.30 Panel Discussion

- Tackling assay validation and ensuring markers are clinically applicable for expedited drug development
- Finding the specific driver of disease: How far can current technologies take us?
- Cost vs quality: Avoiding false positives by finding the right, cost-effective technology for your biomarker

Benoit Destenaves
Director & Precision Medicine Lead
AstraZeneca

Hua Fang
Clinical Biomarker Lead, Immuno-Oncology, Oncology Early Clinical Development
AbbVie

Christina Bender
Exploratory Biomarker & Oncology Commercialization Lead
Bristol-Myers Squibb

17.15 Chair's Closing Remarks & End of Day One

CONFERENCE DAY TWO
WEDNESDAY, FEBRUARY 12, 2020

Robert McCormack
Independent

8.50 Chair's Opening Remarks

Executing Clinical Trials to Effectively Prove the Clinical Utility of Liquid Biopsy & Inform Patient Treatment Decisions

Sarah Paul
Senior Scientific Manager & Biomarker Lead
Genentech

9.00 Demonstrating Clinical Utility of Blood Testing

- Genentech's innovative BFAST trial: Goals, design, and future directions of a blood-only 1L NSCLC trial
- Clinical results from BFAST Cohort A: Blood-identified ALK+ patients treated with alectinib

Jean-Francois Martini
Senior Director, Translational Oncology & Lead, Global Product Development
Pfizer

9.30 Early Monitoring of cfDNA in Lung Cancer: What Can We Learn from the ALK+ NSCLC case?

- Decreased cfDNA dVAF at 6 weeks was associated with response
- Deeper decreases in cfDNA dVAF at 6 weeks were associated with more prolonged PFS and OS
- Early cfDNA dynamics may predict lorlatinib efficacy in ALK-positive metastatic NSCLC

10.00 Morning Refreshments

Mark Routbort
MD, Professor, Hematopathology
University of Texas MD Anderson Cancer Center

10.30 Liquid Biopsy in the Clinic: Lessons from Use in Clinical Care & Clinical Trials

- Become familiar with the 'compartment of origin' challenge for liquid biopsy interpretation
- Compare sensitivity and positive predictive value considerations for liquid biopsy
- Review established and emerging genomic mechanisms of resistance for targeted therapy for solid tumors and the ability of liquid biopsy to detect them

11.00 Session Q+A

Bringing together the perspectives of the session's expert speakers, this is your chance to challenge viewpoints, ask any pending questions or bring new discussion points key to advancing clinical trial design, execution and clinical utility demonstration.

- How can we maximize patient enrolment in large clinical trials?
- Exploring strategies to navigate the analysis of large datasets to analyse relevant, applicable data and draw actionable conclusions to prove utility
- What lessons have been learned from published or unpublished comparative trials to inform end-end drug development?
- Establishing a set of minimal reporting and analysis criteria to be introduced to better understand your study's quality

Sarah Paul
Senior Scientific Manager & Biomarker Lead
Genentech

Jean-Francois Martini
Senior Director, Translational Oncology & Lead, Global Product Development
Pfizer

12.00 Networking Lunch

Meeting the Needs of the Clinician to Improve Patient-Centricity & Standard of Care

Howard Scher
Co-Chair, Head, D. Wayne Calloway Chair & Attending Physician
Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College

13.30 The Oncologist Perspective: Exploring Current Limitations to Implementing & Utilizing Liquid Biopsy in the Clinic

- Real-world examples on how liquid biopsy has aided patient diagnosis and monitoring
- Moving away from the "gold-standard" of tissue biopsy: Exploring healthcare's hesitations
- What's required?: Discussing how healthcare and developers can navigate existing challenges from education to complex price challenges

Robert McCormack
Independent

14.00 Reducing Liquid Biopsy Results to (Routine) Clinical Practice

- Liquid Biopsies have become the preferred sample type in treatment decisions for many cancer patients
- Interpretation of Liquid Biopsy results remain problematic for many technical and administrative reasons, delaying a more rapid uptake for clinical decision-making
- The early results reported here are from an FNIH Consortium to validate commercial ctDNA control material to FDA-requirement levels, enhancing confidence in ctDNA results

14.30 Roundtable Discussion: Liquid Biopsies In the Clinic

- How are perceptions on liquid biopsy beginning to shift in healthcare? Where does future opportunity lie?
- Is liquid biopsy becoming more widely accepted in pathology?
- How do we combat the cost challenges associated with large randomized clinical trials?
- How can effective partnerships and wider industry advancements help drive patient-centricity in personalized therapeutics?

Robert McCormack
Independent

15.30 Chair's Closing Remarks & End of 4th Liquid Biopsy for Precision Oncology Summit 2020

"Thanks for the great meeting! I learned very helpful information and met potential collaborators here."

OUR 2020 PARTNERS

WHY PARTNER?

To unite the right partners that, together, advance and deliver innovative liquid biopsy solutions for drug developers.

Liquid Biopsy for Precision Oncology Summit is back for its 4th year to unite dedicated biopharma and clinical teams to improve the clinical applications of liquid biopsies. A dedicated platform for pharma, biotech, healthcare and diagnostic providers, this meeting explores the latest innovations in liquid biopsy technologies while addressing the field's many unmet needs and challenges.

Partner with us to:

Showcase your expertise to leading organizations through an exhibition space or as an expert speaker

Create connections with the most influential precision medicine leaders striving for improvements on current technologies

Position yourself in the precision medicine community as the go-to market leader

Cement existing relationships through speed networking, personal introductions and multiple industry-wide touch points

GUARDANT

Lead Partner

Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with biopharmaceutical companies to prospectively screen patients for trial enrollment, develop companion diagnostics to support clinical adoption, and use retrospective analysis for early insights into patient response and tumor evolution, as well as accelerate the development of new therapies.

www.guardanthealth.com

epic sciences

Program Partner

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences' mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells. Epic Sciences has partnered with Genomic Health to commercialize the Oncotype DX AR-V7 Nucleus Detect test, which helps with therapeutic decisions between taxane chemotherapy or androgen-directed therapeutics in metastatic castrate-resistant prostate cancer.

www.epicsciences.com

GET INVOLVED

Sam Sarwar
Director of Engage
Tel: +44 (0) 203 141 8716
Email: sam.sarwar@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.lbx-summit.com/take-part/register

Tel: +1 617 455 4188

Email: info@hansonwade.com

1. Radically improve trial reliability through advanced technologies, accurate validation and robust evidence build
2. Address the needs of clinicians for informed drug development and advanced patient-centricity
3. Develop improved commercial strategies and meet potential collaborators to expedite therapeutic success

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: info@hansonwade.com

Attendance to the 4th Liquid Biopsy for Precision Oncology Summit is free for Drug Developers

	Register & Pay Before 15/11/19	Pre-Event Registration	On The Door
Drug Developer (Conference Only)	FREE	FREE	FREE
Service Provider (Conference Only)	$2,399.00 **SAVE $900**	$2,999.00	$3,299.00

The event is operating with limited capacity. To apply to attend please email info@hansonwade.com. A member of our team will get back to you to confirm attendance.

***Drug Developer Complimentary Passes and Cancellation Fee**
By registering you agree to Hanson Wade charging a "no show" compensation fee of:
a) $100 for attendance to the main conference only
b) $150 for attendance to both the main conference and pre-conference workshop day
c) $50 for attendance to the pre-conference workshop day only

Who is eligible for a complimentary drug developer pass?
Eligibility criteria states that a "drug developer" must have a pipeline candidate and must not provide solutions or services for a fee to any other company.

All bookings under the drug developer category are subject to organizer approval. T&Cs apply*

If you cancel your registration 2 weeks before the first day of the conference you will not be charged. You can change your pass name at any stage, but if you do not show without prior notice, you will incur the penalty fee.

Payment can be made by credit card, bank transfer or invoice.

VENUE

Hilton La Jolla Torrey Pines
10950 North Torrey Pines Road
La Jolla, CA, 92037

For further information or assistance, please visit www.hilton.com

Code: 14725